US Patent Issued to Stemline Therapeutics on July 15 for "Combination therapy method of treating myeloproliferative neoplasms with a diphtheria toxin-human interleukin-3 conjugate in combination with other agents" (New York Inventor)

ALEXANDRIA, Va., July 16 -- United States Patent no. 12,357,700, issued on July 15, was assigned to Stemline Therapeutics Inc. (New York).

"Combination therapy method of treating myeloproliferative neoplasms with a diphtheria toxin-human interleukin-3 conjugate in combination with other agents" was invented by Ivan Bergstein (New York).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides methods for treating or inhibiting a myeloproliferative neoplasm (MPN) in a subject in need thereof, comprising administering to the subject a diphtheria toxin-human interleukin-3 conjugate (DT-IL3) and one or more Jak inhibitors and/or one or more hypomethylating agents."

The patent was filed on Oct...